Glucocorticoids and non-alcoholic fatty liver disease

The Journal of Steroid Biochemistry and Molecular Biology
Conor P WoodsJeremy W Tomlinson


Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the global obesity and metabolic disease epidemic and is rapidly becoming the leading cause of liver cirrhosis and indication for liver transplantation worldwide. The hallmark pathological finding in NAFLD is excess lipid accumulation within hepatocytes, but it is a spectrum of disease ranging from benign hepatic steatosis to steatohepatitis through to fibrosis, cirrhosis and risk of hepatocellular carcinoma. The exact pathophysiology remains unclear with a multi-hit hypothesis generally accepted as being required for inflammation and fibrosis to develop after initial steatosis. Glucocorticoids have been implicated in the pathogenesis of NAFLD across all stages. They have a diverse array of metabolic functions that have the potential to drive NAFLD acting on both liver and adipose tissue. In the fasting state, they are able to mobilize lipid, increasing fatty acid delivery and in the fed state can promote lipid accumulation. Their action is controlled at multiple levels and in this review will outline the evidence base for the role of GCs in the pathogenesis of NAFLD from cell systems, rodent models and clinical studies and describe interventional strateg...Continue Reading


Jun 1, 1995·Metabolism: Clinical and Experimental·A V BocharovR Bertolotti
Apr 29, 1998·Biochemistry and Molecular Biology International·A M Giudetti, G V Gnoni
Mar 20, 1999·The Journal of Clinical Endocrinology and Metabolism·P M StewartC H Shackleton
Mar 4, 2000·QJM : Monthly Journal of the Association of Physicians·T P van StaaC Cooper
Dec 4, 2003·European Journal of Endocrinology·A G RockallR H Reznek
Apr 27, 2005·Endocrinology and Metabolism Clinics of North America·Wiebke Arlt, Paul M Stewart
May 3, 2005·The Journal of Clinical Investigation·Kerry L DonnellyElizabeth J Parks
Aug 20, 2005·Diabetic Medicine : a Journal of the British Diabetic Association·G TargherG Falezza
Mar 17, 2006·Physiology & Behavior·Susanne E la Fleur
Aug 11, 2006·Journal of Hepatology·Mariana MachadoHelena Cortez-Pinto
Aug 22, 2006·Metabolism: Clinical and Experimental·Dale S EdgertonAlan D Cherrington
Aug 2, 2007·American Journal of Physiology. Endocrinology and Metabolism·Magalie BerthiaumeYves Deshaies
Aug 11, 2007·Molecular and Cellular Endocrinology·Olivier Kassel, Peter Herrlich
Mar 26, 2008·Journal of Lipid Research·Peixiang ZhangKaren Reue
Jul 31, 2008·Clinical Endocrinology·Sarah KonopelskaMarcus Quinkler
Aug 14, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Z MichailidouK E Chapman
Sep 3, 2008·Cell Metabolism·Ulrike LemkeStephan Herzig
Feb 19, 2009·International Journal of Obesity : Journal of the International Association for the Study of Obesity·M BerthiaumeY Deshaies

❮ Previous
Next ❯


Mar 22, 2016·European Journal of Clinical Investigation·Jorien Werumeus BuningRobin P F Dullaart
Oct 21, 2016·Journal of Molecular Endocrinology·Ewa Harasim-SymborAdrian Chabowski
Apr 1, 2016·Journal of Gastroenterology and Hepatology·Karn WijarnpreechaPatompong Ungprasert
Jan 6, 2018·The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology·Mina KimIn Kyeom Kim
Aug 31, 2017·The Journal of Endocrinology·Adrián Báez-RuizRuud M Buijs
Feb 24, 2018·F1000Research·Jens FreeseHelmut Lötzerich
Jan 26, 2018·Cell Death & Disease·Alessandro SartiniErica Villa
Aug 8, 2019·Journal of Applied Toxicology : JAT·Erika Ramos-Tovar, Pablo Muriel
Mar 27, 2018·Journal of Clinical and Translational Hepatology·Benjamin L Woolbright, Hartmut Jaeschke
Oct 28, 2019·Expert Review of Gastroenterology & Hepatology·Yu JiYuchuan Ding
Sep 20, 2019·International Journal of Molecular Sciences·Su Jin LeeOh-Shin Kwon
Mar 1, 2020·International Journal of Molecular Sciences·Chien-Lin LuYee-Yung Ng
Apr 9, 2020·Journal of Biochemical and Molecular Toxicology·Raju NagarajuPadmanabhan S Rajini
Aug 29, 2020·The Journal of Pharmacy and Pharmacology·Thamires Barros TavaresCristiane Aguiar da Costa
Sep 25, 2017·Hormone Molecular Biology and Clinical Investigation·Melania GagginiAmalia Gastaldelli
Aug 20, 2018·Digestive Diseases and Sciences·Akshay ShettyWing-Kin Syn
May 6, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Leili RahimiFaramarz Ismail-Beigi
Mar 25, 2020·Animals : an Open Access Journal From MDPI·Wenqing MeiRuqian Zhao
Aug 23, 2019·HPB : the Official Journal of the International Hepato Pancreato Biliary Association·Ahad EshraghianSeyed Ali Malek-Hosseini
Jan 14, 2021·International Journal of Molecular Sciences·Carine BeaupereGhislaine Guillemain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Current Opinion in Clinical Nutrition and Metabolic Care
Mariana Machado, Helena Cortez-Pinto
Mediators of Inflammation
Elizabeth HijonaLuis Bujanda
Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis
Alba BerlangaTeresa Auguet
Annual Review of Pathology
Dina G TiniakosElizabeth M Brunt
Gastroenterology Nursing : the Official Journal of the Society of Gastroenterology Nurses and Associates
Stacee M Lerret, Joseph A Skelton
© 2021 Meta ULC. All rights reserved